Information Library
Results for: The New Health
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
FSPs: Ranging from Tactical to Strategic Models
White Paper — January 4, 2012
Biopharma companies can choose from a range of outsourcing models as they seek to respond effectively to the ever-changing conditions in the New Health. -
Strategic Alliances
White Paper — December 5, 2011
Strategic alliances with specialized external partners allow companies to increase agility and the efficiency of processes, variablize resources and raise the number of promising drug candidates in their pipeline. -
Re-ignite Product Development and Sales with Data Insights: Fueling Innovation Fact Sheet
Brochure — November 17, 2011
What Will Drive Biopharma’s Future? The long-dreaded crisis is staring us all in the face: What will take the place of expiring blockbusters with few prospects in hand? Spending on R&D more than doubled after 2002, but the output doesn’t match the investment. The number of new molecular entities has remained a disappointment, averaging only around 20 per year in the US. The big question is how can drug developers carve out a strategic path to innovation? -
Market Intelligence - When There's No Room for Error Fact Sheet
Brochure — November 17, 2011
In the world of biopharmaceutical development, market researchers are in the hot seat. Crucial decisions hinge on research results more than ever, and each decision must be made even faster to have real impact. -
Podcast: Strategic Considerations for Biosimilar Development & Commercialization
Hear from the Experts — September 30, 2011
Deepa Dahal, Principal Consultant, Consulting at Quintiles, and Dr. Nigel Rulewski, Vice President of Global Strategic Drug Development, emphasize an integrated approach to biosimilar development and commercialization. -
An Integrated Approach to Biosimilar Development & Commercialization
White Paper — September 29, 2011
As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. -
Partnering to Maximize Rewards in Pharmerging Markets
White Paper — September 15, 2011
In the past few years so-called “pharmerging” markets have been heralded as the hottest growth area for biopharmaceutical drugs. With large populations, growing disposable income and unmet medical needs, these markets have seen doubledigit growth rates in pharmaceutical spending. -
The New Health
White Paper — August 23, 2011
In 2010, Quintiles advanced the concept of the New Health, our perspective on the fast-morphing biopharma landscape, where the rules are changing on all fronts. -
Make Smarter Choices
Video — July 22, 2011
In your world, every grain of data matters — and every minute counts. To make the most of what you’ve got, turn to Model-Based Drug Development. -
Methods Matter
White Paper — July 18, 2011
As healthcare decision making becomes more complex, stakeholders are demanding real-world evidence tailored to their own individual needs.
